High-risk, non-muscle-invasive bladder cancer is defined as any transitional cell carcinoma (TCC) of the bladder that is high-grade, whether it is primary or recurrent. This high-risk group ...

Medically reviewed by Steffini Stalos, DO Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating ...

Over the last years, many biological markers emerged that act as an adjunct for the detection of early bladder cancer recurrence. Some of these markers had a proven better sensitivity and ...

High-grade tumors have an aggressive appearance under a microscope ... At Johns Hopkins, we have a team of specialist in the Greenberg Bladder Cancer Institute who work together to treat and manage ...

Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).

Innovative fluorescence-based diagnostic system identifies early-stage bladder cancer with 90% accuracy, utilizing untreated ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...